Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
Reuters NewMedia - July 14, 2009
* 10 mln pounds for public-private partnership R&D
* Free voluntary licence for abacavir granted to Aspen
LONDON, July 14 (Reuters) - GlaxoSmithKline <GSK.L> plans to invest up to 60 million pounds ($97 million) over 10 years to improve research, development and access to AIDS drugs in Africa, the world's second biggest drugmaker said on Tuesday.
It has also agreed a new free voluntary licensing agreement for AIDS drug abacavir, or Ziagen, with South African generic drugmaker Aspen Pharmacare <APNJ.J>, in which it has a 16 percent stake. Aspen will manufacture a cheaper generic version of the drug.
The latest steps, announced by Glaxo Chief Executive Andrew Witty on a visit to Kenya, follow pressure from campaigners and some governments for drug companies to do more to get life-saving medicines to the poor, particularly in sub-Saharan Africa.
Glaxo took a lead in February by promising to place many of its patents on drugs for tropical diseases into a free "pool", but it stopped short of offering patents on medicines for HIV/AIDS, which it does not consider to be a neglected disease.
"Up until now I've not really seen the articulation of how a patent pool in this particular area (HIV/AIDS) would change things dramatically," Witty told reporters in conference call.
"The patent pool on neglected diseases was because there was really no research going on in that area -- HIV is not a neglected disease."
So far Glaxo is the only big drug company to have committed to pool some of drug patents, although it was joined in the initiative last week by U.S. biotech Alnylam Pharmaceuticals <ALNY.O>. Glaxo hopes others will follow suit. Its new investments will see up to 50 million pounds channelled into a fund to support non-governmental organisations working with pregnant women to prevent mother-to-child transmission of HIV.
A further 10 million pounds in seed funding will go to support public-private partnership work in developing AIDS medicines specifically for children. ($1=.6147 pounds) (Reporting by Ben Hirschler; Editing by Greg Mahlich)
090714
RE090709
Copyright © 2009 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .